FIGURE 2.

Univariate impact of covariates on Belzutifan AUC_ss (μg∙h/mL) (Study 4). Covariate effects were expressed as a percentage change from the typical value of the reference patient (i.e., a “typical” individual with the specified covariates). The category “extensive CYP2C19 metabolizer” includes all non‐poor metabolizers (i.e., intermediate to ultra‐rapid metabolizers). Extensive/intermediate UGT2B17 metabolizer denotes a patient with intermediate UGT2B17 effect on CL/F and either intermediate or extensive UGT2B17 effect on bioavailability (categories pooled for effect on F). For continuous covariates, green bars represent the range of exposures between the 5th and 95th percentiles of observed covariate values. AUC_ss, area under the concentration vs time curve at steady‐state; CL/F, apparent clearance; CYP2C19; cytochrome (CYP) 2C19; F, bioavailability, FFP, oral compressed fit‐for‐purpose tablet; FMF, film‐coated tablet, the final market formulation; PI, prediction interval; UGT2B17, uridine 5′‐diphospho‐glucuronosyltransferase (UGT) 2B17.